Vivolta and Neurochase to produce brain therapy catheters

New long-term partnership to address neurological disorder treatments

Vivolta, a specialist in medical electrospinning solutions, has entered a long-term partnership with UK-based Neurochase to manufacture electrospun micro-catheters for advanced brain therapies.

This partnership aims to enhance the treatment of neurological disorders, which affect nearly a billion people in the US and Europe.

Neurochase is developing a scalable system for delivering therapies directly to the brain using Convection Enhanced Delivery (CED). This technique allows drugs to bypass the blood-brain barrier and reach deep brain structures through micro-catheters. By generating a pressure gradient at the catheter tip, the drug is evenly distributed, maximising its therapeutic effect.

Denis Leissing, CEO of Vivolta, highlighted the significance of the partnership: “This partnership builds on our already successful product development work with Neurochase, establishing a long term manufacturing relationship. It is a great example of our full suite of electrospinning solutions from product development to commercial manufacturing.

He added: “We’re proud that our team’s expertise along with our unique and scalable MediSpinTM manufacturing system will help bring this high-performance micro-catheter to patients who will benefit.”

Neurochase’s CEO, Sharon Kane, echoed this sentiment, stating, “The Vivolta relationship has been hugely important in finding a solution to one of the most technically challenging components of the Neurochase delivery system. We are excited to be taking our transformative product forward together into large scale manufacture with such a knowledgeable, skilled and motivated team.”

The two companies first partnered in 2022 to develop the electrospun component of Neurochase’s micro-catheter delivery system.

Vivolta will exclusively manufacture these components using their automated MediSpinTM production system, known for its ability to produce electrospun medical products at scale.

Neurochase plans to begin clinical trials of its micro-catheter delivery system in 2025, collaborating with clients to treat conditions like Parkinson’s Disease, Huntington’s Disease, brain tumours, and Fronto Temporal Dementia.